Left Ventricular Assist Device (LVAD) and Associated Thrombocytopenia

By SWA

An LVAD (Left Ventricular Assist Device) is a mechanical device that supports heart function and blood flow in individuals with weakened or failing hearts, typically due to conditions like heart failure. It is surgically implanted to take over the pumping function of the left ventricle, which is the heart’s main pumping chamber responsible for sending oxygen-rich blood to the rest of the body.

Key Points about LVAD:

  1. Purpose: The LVAD helps the heart by mechanically pumping blood, which reduces the heart’s workload and helps improve blood circulation throughout the body.
  2. Benefits: It can significantly reduce symptoms such as fatigue and shortness of breath, improve quality of life, and extend survival in patients with severe heart failure.
  3. Use Cases: LVADs are commonly used as a bridge to heart transplantation, as a destination therapy for those not eligible for a transplant, or as temporary support in cases of acute heart failure.

LVAD-Associated Thrombocytopenia:

The image discusses LVAD-associated thrombocytopenia, a condition where the platelet count drops below normal levels, which is a known complication in patients with LVADs.

  • Our Patient: The table on the left shows a patient’s platelet counts after an LVAD implantation, showing a decline in platelet levels, which is concerning for thrombocytopenia.
  • Literature Data: The graph on the right summarizes findings from a study of 235 patients who underwent LVAD implantation:
    • Thrombocytopenia was defined as a platelet count of <75 k/µL.
    • The study showed that platelet counts initially dropped after the procedure, reaching a low point at around three days post-operation, before eventually increasing.
    • Thrombocytopenia was more common in women than men, being seven times more likely to develop in women.

Understanding these patterns helps manage and anticipate complications in patients with LVADs, leading to better patient care and outcomes.

 

references related to LVADs and LVAD-associated thrombocytopenia that can provide more in-depth information:

  1. Kirklin JK, Pagani FD, Kormos RL, et al. "Eighth annual INTERMACS report: Special focus on framing the impact of adverse events." J Heart Lung Transplant. 2017 Oct;36(10):1080-1086.

    • This report provides a comprehensive overview of complications associated with LVADs, including bleeding and thrombocytopenia.

  2. Goldstein DJ, John R, Salerno C, et al. "Algorithm to reduce stroke risk in patients with ventricular assist devices." J Am Coll Cardiol. 2018 Aug 21;72(8):964-989.

    • This article addresses complications related to LVADs, including hematological issues like thrombocytopenia, and discusses risk management strategies.

  3. Xie A, Shih E, Skerrett DL, Uriel N. "Mechanical unloading of the failing heart and thrombotic risk." Thromb Haemost. 2016;116(4):660-676.

    • A detailed look at how mechanical heart support devices, such as LVADs, impact thrombotic and hematological complications.

  4. Uchida K, Minami Y, Sawa Y. "Platelet consumption in patients with continuous-flow left ventricular assist devices." Eur J Cardiothorac Surg. 2016 May;49(5):1414-1420.

    • This study specifically examines platelet consumption and thrombocytopenia in patients with continuous-flow LVADs.

  5. J Cardiothorac Vasc Anesth. 2022 May;36(5):1502-1504.

    • This reference corresponds to the specific study cited in the image, which examines the incidence of thrombocytopenia in patients who have undergone LVAD implantation, highlighting sex differences in its development.

These references can provide more insights and data regarding LVAD-associated thrombocytopenia and management approaches for patients with LVADs.

© 2000-2025 Sieglinde W. Alexander. All writings by Sieglinde W. Alexander have a fife year copy right. Library of Congress Card Number: LCN 00-192742

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more